This site is intended for health professionals only

Drug fights cancer on two fronts


An anti-malarial drug could soon be used as a new weapon in the treatment against cancer, research has indicated.

Curaxins involves synthetic small molecules designed to target certain functions in the body that are altered when a patient suffers from cancer.

Cleveland BioLabs (CBLI) said its curaxin molecules cause the activation of the tumour suppresser protein p53, which commonly becomes inactive in cancer, and suppresses NF-kB signalling – a mechanism seen in the majority of tumours that encourages the survival of cancerous cells.

A study looking at the founding molecule in the curaxin program – CBLC102 – using patients who had previously received hormonal treatment for advanced prostate cancer and chemotherapy recorded a partial response in one patient, while 50% of the study group exhibited a decrease or stabilisation in the speed of prostate cancer progression.

Dr Michael Kurman, clinical oncologist and chief medical officer of CBLI said: “We are satisfied with the outcome of this trial, which demonstrated indications of activity and a remarkable safety profile in one of the most difficult groups of cancer patients.”

Copyright Press Association 2009

Cleveland BioLabs

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine